Featured Article

Diabetic macular edema (DME) is an eye condition which can lead to vision impairment and even blindness, often as a result of the strain put on the eye caused by diabetes. While having to live with DME is a challenging experience, there is some good news - the recent availability of a prescription eye-injection treatment known as Eylea (or aflibercept) has revolutionized the treatment of DME in a way that can positively change the lives of many.

What are the positive effects of Eylea?

Eylea is a retinopathy drug administered via injection into the eye. It works by preventing new blood vessels from forming in the eye, which is the primary cause of DME. What makes Eylea such a beneficial treatment for DME is its effectiveness over time. Studies have shown that when Eylea is given injections every 4 weeks, patients saw an improvement in their vision in as little as 12 weeks. Even after 24 weeks, those improvements remained.

In addition, Eylea has been found to be long lasting - meaning that patients do not have to administer injections as frequently. While this depends on the individual, many patients need to receive no more than a maintenance dose of two injections per year. This means patients can experience fewer hospital visits, and the stress associated with them.

The accessibility of Eylea also adds to its value. As it is a prescription eye-injection, it is widely available throughout Europe and more recently the United States, meaning that anyone who has DME can get easy access to the treatment which can make all the difference.

The impact of Eylea

Eylea has had a profound impact on the lives of those with DME. Considering DME can lead to irreversible damage to the eyes, Eylea has made a huge difference. It has, in many cases, prevented blindness and allowed people to maintain their vision.

Compared to alternatives to Eylea, it is also relatively non-invasive and easy to administer. For many people, receiving this type of treatment is preferable to frequent hospital visits and intrusive surgeries. The fact that it has been found to be successful over the long term means that for many sufferers, they can experience a more comfortable existence free from the fear of developing further conditions.

Conclusion

Eylea has been a revolution in the treatment of DME. Its success rate of stabilizing and improving vision in those suffering from DME, combined with its accessibility and relative non-invasiveness, has made it a valuable treatment not only for those suffering from DME, but the medical industry as a whole. With more and more people suffering from this eye condition due to diabetes, Eylea offers the hope of a longer, healthier, and happier life.